Navigation Links
MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
Date:4/27/2009

VALENCIA, Calif., April 27 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2009 first quarter financial results on Monday, May 4, 2009.

Management of the Company will host a conference call to discuss the first quarter financial results and other Company developments at 4:00 PM EDT on May 4, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (888) 566-0513 or (203) 369-3063. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA(R), an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of its press releases as well as additional information. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind Submits NDA for AFRESA for Treatment of Diabetes
2. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
3. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
4. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
5. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
6. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
7. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
8. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
9. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
10. MannKind to Present at the UBS Global Life Sciences Conference
11. MannKind Corporation Reports Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the ... lead to new and improved ways of treating coronary artery disease (CAD). Lam ...
(Date:3/27/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is now offering a ... consumers who want to have their DarioHealth products reimbursed ... alliance agreements with partners across the U.S. who will ... approved, will supply and bill the customer,s insurance for ...
(Date:3/24/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... and patent-protected processes to develop and market advanced products ...  that it will present at the Needham Healthcare Conference ... H. "Pete" Petit, Chairman and CEO, Michael J. ... , EVP and Chief Commercialization Officer, and Mark ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Strategic Business Report" report to their offering. ... This report analyzes the Global ... Annual estimates and forecasts are provided for the period 2014 through ... research. The report profiles 25 companies including many ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):